Magneto's EIC Accelerator Catheter Pulls Clots With Voltage

Mechanical thrombectomy devices grip a blood clot by pressing outwards against the artery. That limits how far into narrow vessels they reach, and parts of the clot break off on the way out. Magneto Thrombectomy Solutions, founded in Israel in 2016 inside Peregrine Ventures' Incentive incubator, applies a voltage instead: the negatively charged ions of the clot bond to a positive electrode on the catheter, which the company compares to a magnetic grip, so the clot is pulled toward the device rather than squeezed against the vessel wall.

The EIC Accelerator selected the project, MGN-2024-10, at its October 2024 cut-off for blended finance, and CORDIS records a grant of €2,499,875 from July 2025 to June 2027 for the eTrieve system in stroke and pulmonary embolism. The project puts the total addressable market at €5 billion in the EU and US, of which €1 billion is serviceable, at $3,000 to $5,000 per stroke device and $10,000 per pulmonary embolism procedure.

Charge instead of force

The physical argument is about the clot's material. Fibrin carries a high electrical charge density, so applying voltage makes the clot adhere strongly to the catheter's active electrode, and the company says in-vitro tests covered the full range from soft red cell-rich clots to firm fibrin-rich chronic ones. The pulmonary embolism kit pairs that catheter with eFlex, a large-bore ultra-flexible aspiration catheter, so proximal and distal emboli can be removed in one session. The claimed benefits are no thrombolytic drugs, no intensive care stay, no capital equipment, and less fragmentation and vessel damage.

The stroke device is a microcatheter for the neurovasculature, and the pitch there is that it replaces both the retriever and the push-outward mechanism: fewer devices, access to more distal vessels, less fragmentation.

Ten patients, four years ago

The clinical record is thin. In May 2022 Magneto reported a prospective, single-arm, multicentre first-in-human study of the eTrieve PE kit in 10 patients with acute pulmonary embolism at three sites in Denmark and Poland, as Venous News reported. The procedures were done under light sedation, there were no device-related complications, and the primary endpoint, a reduction in the right-to-left ventricular diameter ratio at 48 hours, was met. The data were presented at Biomed Israel 2022 and have not appeared in a peer-reviewed publication.

Since then the company's website reports that a first-in-human study of the stroke microcatheter is ongoing and that it is planning an international study to support marketing approvals worldwide. Both devices are labelled investigational. The physician testimonials on the site are favourable but are quotes rather than data, and CORDIS shows no periodic report for the EIC project.

1. First-in-human safety in PEReported10 patients, no device-related complications, 2022.
2. Peer-reviewed publicationNone foundResults presented at a conference only.
3. Stroke clinical dataStudy ongoingNo patient numbers or results published.
4. Pivotal study and approvalPlannedA study of more than 100 patients was announced in 2022; not reported as started.

A quiet balance sheet

Magneto has announced no venture round. It came out of an incubator whose model is to fund early medical device work, and the EIC grant of €2.5 million is the largest sum attached to it in public records. The award was blended finance, and no EIC Fund equity investment has been announced. The company's accounts are not public, and third-party databases disagree with each other on its total funding, so none of their figures are used here.

European hospitals as the test bed

The clinical work so far has been done in Europe, at hospitals in Denmark and Poland, and the EIC grant now pays for the next stage, which is exactly the role the instrument is meant to play for a medical device company that has passed first-in-human but cannot yet fund a pivotal trial. For the EU, a thrombectomy device that reaches more distal clots would matter in two conditions, stroke and pulmonary embolism, whose incidence rises with an ageing population, as the project summary notes.